LUMCi059-A-1

Iso71LUMCi232KLHL01

General

Cell Line

hPSCreg name LUMCi059-A-1
Cite as:
LUMCi059-A-1
Alternative name(s)
Iso71LUMCi232KLHL01
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 7th June 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Leiden University Medical Center (LUMC)
Owner Leiden University Medical Center (LUMC)
Distributors
Derivation country Netherlands

External Databases

BioSamples SAMEA115597187

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: To be discussed with Karine Raymond
Additional restrictions:

Under MTA request addressed to Karine Raymond

Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Intermediate EBS with cardiomyopathy
Genetic variants
KLHL24 (target)
3q27.1
c.2T>C
Heterozygous
Family history No
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA115711133

Ethics

Also have a look at the ethics information for the parental line LUMCi059-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line LUMCi059-A.

Reprogramming method

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-4
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
EOMES
Yes
GATA4
Yes
FOXA2
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
Vimentin
Yes
CDX2
Yes
Brachyury (TBXT)
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
Nestin
Yes
FABP7
Yes
PAX6
Yes

Microbiology / Virus Screening

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 25
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Intermediate EBS with cardiomyopathy
Genetic modifications
KLHL24 (target)
Isogenic modification
3q27.1
c.2C>T
Heterozygous
Genetic modification to repair the disrupted start codon found in the donor line.
Repaired
Genetic modifications not related to a disease
Isogenic modification
3q27.1
c. -3 A>G
Heterozygous
Mutation that allows rapid screening of candidate clones.
Mutated